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Abstract Patients with atrial fibrillation (AF) are com-
monly managed with rhythm control strategy, but the
natural history of this common arrhythmia leads itself to
progression from paroxysmal to persistent or permanent
AF, and recurrences are evident despite rhythm control
treatments using cardioversion or catheter ablation.
Numerous clinical factors have been associated with out-
comes of rhythm control or arrhythmia progression in
patients with AF. The more common factors have been
used to formulate risk stratification scores, to help predict
the outcomes of rhythm control treatments or AF pro-
gression. This review article provides an overview on the
published clinical risk scores related to outcomes of rhythm
control strategy or AF progression.
Keywords Atrial fibrillation  Rhythm control 
Cardioversion  Catheter ablation
Introduction
Patients with atrial fibrillation (AF) are commonly man-
aged with rhythm control strategy, but the natural history
of this common arrhythmia leads itself to progression from
paroxysmal to persistent or permanent AF, and recurrences
despite rhythm control treatments using cardioversion or
catheter ablation (CA). The latter has been shown to have
superior efficacy in the short- or long-term comparison
with antiarrhythmic drugs (AAD) even in patients with
persistent AF [1, 2]. As an interventional procedure, CA
therapy still has various issues including arrhythmia
recurrence, procedural complications, and high expenditure
which are important considerations when physicians have
to make decisions whether CA is appropriate or not. Ulti-
mately, a decision of atrioventricular junction ablation with
permanent ventricular pacing may also be considered
rather than AF ablation in highly symptomatic patients
with high risk of AF recurrences [3].
The recurrence rate of a single CA procedure ranges
from 30 to 50% [4]. Many clinical factors such as older age
[5], non-paroxysmal AF [6], left atrial (LA) size [7], female
sex [8], coronary artery disease (CAD) [4], hypertension
(HTN) [9], diabetes mellitus (DM) [10], untreated
obstructive sleep apnea (OSA) [4], metabolic syndrome
(MetS) [11], body mass index (BMI) [12], chronic kidney
disease (CKD) [13], heart failure (HF) [14, 15], early
arrhythmia recurrence (ER) [16], and prior refractoriness to
antiarrhythmic drugs [17] have been reported as predictor
of recurrence after CA (see Table 1). Of the numerous
clinical factors that have been associated with outcomes of
rhythm control or arrhythmia progression in patients with
AF, those which are more common have been used to
formulate risk stratification scores, to help predict out-
comes of rhythm control or arrhythmia progression.
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Several such scores have been published, as summarized in
Table 2.
The objective of this review article is to provide an
overview on the published clinical risk scores related to
outcomes of rhythm control strategy or arrhythmia
progression.
Search strategy
Comprehensive literature search was performed using
MEDLINE for studies reporting on the predictive scores of
AF recurrence after CA or AF progression. Search terms
included ‘‘atrial fibrillation’’, ‘‘ablation’’, ‘‘recurrence’’,
‘‘outcome’’, ‘‘progression’’, and ‘‘score’’. The articles
retrieved by the search were selected by title and abstract
screening. Nine relevant clinical scoring systems have been
reported (Table 2). We summarized prediction, with c-in-
dexes or area under the curve (AUC), or reclassification or
discrimination indexes, where reported. As most clinical
scores only had one associated paper related to rhythm
control or arrhythmia progression, no meta-analysis was
performed, given the heterogeneity of the patient popula-
tions studied.
The HATCH score
The HATCH scoring system was first developed to predict
the clinical progression of paroxysmal to persistent AF
[18]. In the original description, 1219 patients from the
Euro Heart Survey on AF were included and were observed
for more than 1 year. Different clinical variables were
studied to evaluate the predictive value on AF progression,
and heart failure (H), older age (A), previous transient
ischemic attack (TIA) or stroke (T), chronic obstructive
pulmonary disease (COPD,C), and hypertension (H) were
identified as independent predictors of AF progression.
Hypertension, age C75 years, and COPD each were
assigned 1 point, while TIA or stroke, and heart failure
were scored 2 points, with the HATCH score ranging from
0 to 7 points. In the original study, nearly 50% of patients
Table 1 Examples of risk factors for AF recurrence after catheter ablation
Risk factors CA CBA References
LAD H H Zhuang [7], Chao [57], Miyazaki [58], Liu [59]
LAD, PeAF, AF history H Miao [60]
Non-PAF H Konrad [6], Chang [61]
Epicardial adipose tissue thickness H Chao [62], Kim [63]
Early recurrence H H Miyazaki [16], Evranos [64], Shim [65]
Obstructive sleep apnea H Naruse [66]
Inflammatory factors H Wu [67]
Duration of AF, gender H Zhang [68]
RA enlargement, C2 procedure times, AF duration H Zhao [69]
Uric acid, LAD, early recurrence H Canpolat [70]
Low BMI, PeAF H Fujino [71]
PR interval H Park [72]
Duration of AF, LAD, number of ineffective AAD H Takigawa [73]
Age, LAD, BMI, valvular heart disease, PR interval H Wu [74]
TGF-beta1 H Canpolat [75]
Renal dysfunction H Li, 2014 [13], Neumann [76]
COPD H Gu [77]
Left ventricular systolic dysfunction H Anselmino [14]
Left ventricular diastolic dysfunction H Kumar [15]
Prior AAD failure, non-PAF, hypertension H Khaykin [17]
Hypertension H Wang [9]
Metabolic syndrome H Lin [11]
Diabetes mellitus H Anselmino [10]
Age H The [5]
Female H Zylla, 2016 [8]
AAD antiarrhythmic drug, AF, atrial fibrillation, BMI body mass index, CA catheter ablation, CBA cryoballoon ablation, COPD chronic obstruct
pulmonary disease, LAD left atrial diameter, non-PAF non-paroxysmal AF, PeAF persistent AF
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with a HATCH score of[5 progressed to persistent AF,
but only 6% of those with a score of 0 experienced AF
progression. A subsequent study of AF patients who were
awaiting CA found the HATCH score to be a poor pre-
dictor of AF progression [19]. Similar observations were
seen in the Belgrade AF study, which showed that the
HATCH score had only very modest predictive value (c
statistic, 0.6) for the arrhythmia progression in a cohort of
lone AF patients over a 12-year follow-up period [20].
Whether the HATCH score could be used to predict the
outcome after CA of AF was studied by Tang et al. [21] in
488 patients with paroxysmal AF undergoing CA. After
27.4 ± 17.7-month follow-up, 69.93% of patients were
free of late AF recurrence, but the HATCH score was not
an independent predictor of recurrence on multivariable
analysis. Thus, the HATCH could not reliably predict the
outcome after CA.
The predictive value of the HATCH score was further
explored recently. Suenari et al. [22] tested the score in a
670,804 patients’ cohort to investigate its predictive
value of new-onset AF. In this cohort, patients were
20 years older, than in derivation cohort, without AF
history. During a follow-up of 9.0 ± 2.2 years, the AF
incidence increased from 0.8 per 1000 patient-years for
patients with a HATCH score of 0–57.3 per 1000
patient-years for those with 7. After adjustment for
gender and comorbidities, the hazard ratio of each
increment of the HATCH score in predicting new-onset
AF was 2.059 (CI 2.027–2.093, P\ 0.001). The result
showed that the HATCH score was useful in estimation
and stratification of new-onset AF.
The ALARMEc score
The ALARMEc score [23] was first reported as a scoring
system to predict the outcome of AF CA in a study com-
paring the ALARMEc score with the CHADS2 and
CHA2DS2–VASc scores for stroke risk stratification. The
ALARMEc score included five variables, as follows: AF
type (A), Left Atrial size [normalized left atrial area (NLA)
C10.25], Renal insufficiency (eGRF\68 ml/min), Meta-
bolic syndrome and cardiomyopathy (c) with each variable
scoring 1 point, and the score values ranging from 0 to 5
points. The ALARMEc score was tested in only 213
patients with paroxysmal AF or non-paroxysmal AF who
underwent repeated CA. After a follow-up of up to
Table 2 Studies for predictive scores related to outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation
First
author,
year
Scores
(points)
Enrolled
patients
(n)
pAF
(%)
CA protocol AFLAT-
Free (%)
Procedure
times
FU
(months)
C Index/
AUC
Predictive
value
CHADS2/
CHA2DS2–
VASc
compared
Tang
[21],
2012
HATCH
(0–7)
488 100 CPVI 63.93 Single 27.4 ± 17.7 Not
measured
No Not
compared
Maciej
[23],
2013
ALARMEc
(0–5)
213 47 Stepwise* 90 Repeated 24 0.657 vs.
0.533/
0.519
Yes Worse
Ugur
[25]
2013
BASE-AF2
(0–6)
236 79.6 Cryoablation 74.5 Single 20 0.94 (score
C3)
Yes Not
compared
Letsas
[31]
2014
CHADS2
(0–6)/
CHA2DS2–
VASc (0–9)
126 100 CPVI 70.6 Single 16 0.644/
0.627
(score
C2)
Yes –
Kornej
[26],
2015
APPLE (0–5) 261 48 Stepwise* 38.3 Single C12 0.634 vs.
0.538/
0.542
Yes Worse
Roger
[28],
2016
CAAP-AF
(0–13)
937 31.6 Stepwise* 79.1 Repeated 21.6 ± 1.6a 0.650 Yes Not
compared
Mujovic
[29],
2017
MB-LATER
(0–6)
133 69.2 Stepwise* 85 Repeated 29 ± 10.1 0.782 vs.
0.552/
0.519
Yes Worse
AFLAT atrial flutter or atrial tachycardia, AUC area under curve, CPVI circumferential pulmonary vein isolation, FU follow-up, pAF paroxysmal
atrial fibrillation
* Stepwise, necessary additional linear lesion, or complex fractionated atrial electrogram-guided ablation after CPVI
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60 months, only the ALARMEc score (AUC 0.657,
P\ 0.0001) but not CHADS2 (AUC 0.533, P = 0.413) or
CHA2DS2–VASc (AUC 0.519, P = 0.641) score predicted
outcomes after CA.
Another study [24] included 702 patients with AF and
analyzed four of five risk factors in a modified (ARLA-
MEc) score. In this study, MetS and impaired renal func-
tion were independent predictors of AF postablation
outcome, but NLA and AF type were non-predictive. For
the outcome of repeated CA, MetS was not predictive for
late recurrences, but impaired renal function remained a
significant predictive factor. Result of this study had some
difference from the previous one.
BASE-AF2 score
The BASE-AF2 score system [25] comprises six clinical
variables, as follows: Body mass index (BMI)[28 kg/m2
(B), atrial dilatation [40 mm (A), current smoking (S),
early recurrence (E), duration of AF[6 years (A), and non-
paroxysmal AF type (F). Each variable scores 1 point, with
the score range from 0 to 6 points.
This score was tested in a set of 236 patients with
paroxysmal AF who underwent cryoablation, and those
with AF recurrence had higher BASE-AF2 score values,
with a score of C3 points being an independent predictor of
AF recurrence. This score was only tested in patients with
AF undergoing cryoablation and its value in other CA
modalities merits further study.
The APPLE score
The APPLE score [26] was derived from a cohort of AF
patients from Germany and tested in a validation cohort
from the US. This scoring system comprised of five vari-
ables, as follows: Age[65 years (A), persistent AF (P),
impaired eGFR (\60 ml/min/1.73 m2) (P), LA diameter
C43 mm (L), and EF\50% (E). Each variable scored 1
point with the score ranging from 0 to 5 points.
In the derivation cohort, logistic regression analyses
showed that the APPLE, CHADS2, and CHA2DS2–VASc
scores were significant predictors of AF recurrence
between 3 and 12 months. Based on ROC curve analysis,
the APPLE score had a better predictive value compared
with CHADS2 and CHA2DS2–VASc score (c index 0.634
vs. 0.538 and 0.542, respectively, both P\ 0.001). Vali-
dation study [27] of the APPLE score also carried on a
cohort (n = 379) under repeated CA. Compared with
CHADS2 and CHA2DS2–VASc score, the APPLE score
also had better predictive value of AF recurrence after
repeated CA (AUC 0.617 vs. 0.577 and 0.590, respectively,
both P\ 0.001). In the latest validation study, the risk
(OR) of AF recurrence was 2.9, 3.0, and 6.0 for patients
with APPLE score 1, 2, and C3, respectively, when com-
pared to an APPLE score of 0 (all P\ 0.01).
The CAAP-AF score
The CAAP-AF score [28] was initially described in a
derivation cohort of 1125 AF patients and tested in a val-
idation cohort of 937 AF patients who underwent first CA
at the same centre. AF type included paroxysmal AF and
non-paroxysmal AF. The score consisted of the following
variables: CAD (C), LA diameter (A), age (A), persistent
or long-standing AF (P), number of antiarrhythmic drugs
failed (A), and female sex (F), which were independent risk
factors of AF recurrence in the derivation cohort on mul-
tivariable analysis. Accordingly, the C, F, and P criteria
were awarded 1, 1, and 2 points, respectively. The score
was scored 0–4 based on the different LA diameters of
\4.0, 4.0 to\4.5, 4.5 to\5.0, 5.0 to\5.5, and C5.5 cm.
The age criterion was given different points of 0–3 for ages
\50, 50 to\60, 60 to\70, and C70 years. If patient had 1
or 2 antiarrhythmic drug failures, it scored 1 point. When
the number was over 2, it scored two points.
Thus, the CAAP-AF score system comprises six risk
factors and the score ranges from 0 to 13 points. In the
validation cohort, percentage of AF-free patients was
identical to that seen in the derivation cohort (statistic C
0.650 vs. 0.691). Of note, the CAAP-AF score was based
on a single centre experience and AF recurrence was
detected only by 24 h or 7-day Holter but not by loop
recorder implantation.
The MB-LATER score
The recently published MB-LATER score was recently
proposed [29] to predict very late ([12 months) recurrence
of AF (VLRAF) after CA. In this score, five clinical factors
are considered: male sex, bundle branch block, left atrial
size C47 mm, type of AF (paroxysmal, persistent, or long-
standing persistent), and early recurrent AF. The MB-
LATER was derived from a small retrospective cohort and
compared against other clinical scores (APPLE, ALAR-
MEc, BASE-AF2, CHADS2, CHA2DS2–VASc, or
HATCH). When compared to these scores, the MB-
LATER demonstrated better predictive value (AUC 0.782
vs. 0.716, 0.671, 0.648, 0.522, 0.519, or 0.583) and
improved identification of patients with subsequent
VLRAF using decision curve analysis (DCA).
The CHADS2, CHA2DS2–VASc, and R2CHADS2
scores
The CHADS2 (congestive heart failure, hypertension, Age
C75, diabetes mellitus, and stroke/transient ischemic
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attack), CHA2DS2–VASc (congestive heart failure,
hypertension, age C75 years, diabetes mellitus,
stroke/transient ischemic attack, vascular disease, age
65–74 years, and female sex), and R2CHADS2 (renal
dysfunction, congestive heart failure, hypertension, age
C75 years, diabetes mellitus, and stroke/transient ischemic
attack) scores are risk scores for predicting stroke and
thromboembolism [30]. Given that the risk factor compo-
nents of these scores are common cardiovascular risk
factors, it is no surprise that they can be [29] related to
outcomes of rhythm control or arrhythmia progression.
For example, Letsas et al. reported that on univariate
analysis, both CHADS2 and CHA2DS2–VASc scores were
associated with AF recurrence in patients with paroxysmal
AF undergoing a single CA procedure. A score of C2 for
both CHADS2 (AUC 0.644) and CHA2DS2–VASc (AUC
0.627) scores had the highest predictive value for AF
recurrence [31]. Another study [32], which included
patients with paroxysmal AF and persistent AF, reported
that both CHADS2 (HR 1.19, P\ 0.001) and CHA2DS2–
VASc (HR 1.15, P\ 0.0001) scores were good in strati-
fying patients for 5-year outcomes after AF ablation, with
the CHA2DS2-VASc (HR 1.13, P = 0.001) score being
superior to the CHADS2 score for predicting AF
recurrence.
Kornej et al. [33] reported that AF type, LA diameter,
and early recurrence (ER) were significant predictors of
long-term recurrence post AF ablation, and not the
CHADS2, CHA2DS2–VASc, and R2CHADS2 scores.
Reports on the predictive value of these stroke risk scores
on rhythm control outcomes do not appear to have con-
sistent results.
A critique of the published scores
AF recurrence after CA was defined as AF/AT/AFL epi-
sode lasting 30 s with or without symptom recorded over
3 months after the procedure in the derivation or validation
research of all the clinical scores.
Scoring systems described above used different pre-
dictive clinical factors in combination (see Table 3). Some
of these factors like BMI and MetS had conflict results
[11, 12]. One meta-analysis found that recurrence within
30 days, LA diameter of[50 mm, and valvular AF were
the most powerful predictors of CA failure [34].
From the clinical perspective, AF progression could be
defined as development of persistent or long-standing AF
in patients with paroxysmal AF. In the derivation study of
HATCH score, five clinical factors were identified as
independent predictors of AF progression (see Table 3).
Although these factors have previously been reported
separately (see Table 1), the intrinsic mechanistic link and
the development of the substrate for AF or its progression T
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requires further study. The predictive value in AF pro-
gression of the HATCH score is still controversial, but
result of recent validation study on new-onset AF demon-
strated good predictive ability. Clinical applicability of the
HATCH score needs much more evidence to support.
Five scores derived from different cohorts, that is, the
ALARMEc, BASE-AF2, APPLE, CAAP-AF, and MB-
LATER, included the LA size as one of the predictive
variables. Nonetheless, the size of LA was differently
defined in different scores. For example, LA size was
defined as[43 mm in APPLE score,[40 mm in BASE-
AF2 score, [47 mm in MB-LATER, and [50 mm in
ALARMEc score, and stratified into five categories of\40,
40 to \45, 45 to \50, 50 to \55, and C55 mm in the
CAAP-AF score. Given that they were not initially devel-
oped to predict the rhythm outcome following CA, the
CHADS2, CHA2DS2–VASc, R2CHADS2, and HATCH
scores did not include LA size as one of their component
risk factors.
LA enlargement is involved in mechanism of AF for-
mation and progression. Atrial fibrosis may be an important
feature for AF perpetuation, and it may be evaluated using
cardiac imaging [35] or biomarkers [36–38]. Interestingly,
fibrosis may be found in AF patients with no LA
enlargement. Whether these parameters may improve the
predictive value of scores aiming to identify the risk of
arrhythmia progression should be evaluated in the future.
Some of the included risk factors could relate to patho-
physiological changes in the LA. For example, patients
with HTN were found to have increasing size of scar and
low-voltage area in the LA when mapping during the CA
procedure [9]. MetS may play an important role in the
atrial electrical activity by promoting the atrial conduction
disturbances and dispersion of refractoriness between the
right and left atrium [39]. In addition, obesity [40] is
associated with a shortened effective refractory period in
the pulmonary veins.
AF subtype was another variable included in five scor-
ing systems (see Table 3). Electrical changes promoting
arrhythmia perpetuation are induced by the presence of AF
itself, which has also been called ‘‘AF begets AF’’ several
years ago. From the onset of AF, the LA undergoes gradual
electrical and structural remodeling which ultimately forms
a substrate capable to maintain AF. Non-paroxysmal AF
has been associated with lower AF termination rates and
worse outcome after CA compared to paroxysmal AF [6].
The predictive value of AF duration for postablation
recurrence of non-paroxysmal AF has been reported widely
[6, 17, 41].
Early AF recurrence was only included in the BASE-
AF2 and MB-LATER score. As we know, early recurrence
is observed only after CA, and while of limited use in pre-
ablation decision, it might be useful to predict rhythm
outcome following repeated ablation procedures, as a
reconnection of the PV–LA electrical conduction is con-
sidered to be the main mechanism of ER [16] as well as
recurrence [42]. Thus, LA size, AF type, and ER, which
may directly contribute to the AF substrate, should be
considered as most important parameters included within
the five main scoring systems.
Other risk factors were shared in several scores. Age
was risk factor of the HATCH, CHADS2, R2CHA2DS2,
CHA2DS2–VASc, APPLE, and CAAP-AF scores. Heart
failure (HF) was shared in the HATCH, CHADS2, R2-
CHA2DS2, CHA2DS2–VASc, and CAAP-AF score. These
two factors were previously reported elsewhere. Incidence
of HF is increased in AF patients which encourage a
rhythm control strategy [43]. Vice versa, patients with HF
progress to AF more easier than those without and evi-
dence showed that risk profile is shared by HF and AF [44].
Of the five mentioned scores, the ALARMEc, BASE-
AF2, APPLE, CAAP-AF, and MB-LATER scores each
were tested in only one study, and these studies included
patients with different AF types. Only the BASE-AF2 score
used the cryoablation technique which could have had
some influence on the outcome of non-paroxysmal AF
patients. Indeed, cryoablation just performs a circumfer-
ential pulmonary vein isolation (CPVI) and the result in
non-paroxysmal AF ablation may potentially be subopti-
mal with cryoablation [25], although the optimal strategy
for ablation in non-paroxysmal AF still needs to be
established [45]. Compared to the MB-LATER score, the
BASE-AF2 score also had moderate predictive value (AUC
0.648) for VLRAF [25].
The other four studies used radio frequency CA and a
stepwise protocol, especially with non-paroxysmal AF,
where patients would sometime need to have linear lesions
(LL), mitral/tricuspid isthmus ablation, superior vena cava
isolation, or complex fractionated atrial electrogram abla-
tion (CFAE) when AF is continuous after the CPVI
[23, 26, 28]. There were minor differences among the
approaches used in these four studies. Patients from the
CAAP-AF cohort underwent CPVI and roof linear lesions
in both paroxysmal or non-paroxysmal AF, and coronary
sinus ablation was performed. In the derivation cohort of
the APPLE score, electrical cardioversion was used ini-
tially if AF presented at the beginning of the CA procedure.
However, in the validation cohort, cardioversion was used
when AF was continuous after CPVI, roof linear lesion,
mitral linear lesion, base posterior wall lesion, or CFAE,
although the efficacy of additional linear lesion and CFAE
on sinus rhythm maintaining after CA has not been firmly
established [46, 47]. None of these studies provided much
detail on ablation parameters, complication, and AF ter-
mination of the procedure, which might influence the acute
procedural rate of AF. As far as we known, new techniques
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are evolving within CA such as contact force catheter [48]
and second-generation cryoballoon [49], new mapping
systems (e.g., focal impulse and rotor or high dominant
frequency mapping) [50, 51], and new ablation technique
(e.g., hybrid or epicardial ablation) [52] have influenced the
efficiency and safety of AF ablation. Hence, the predictive
value of these clinical scores would need to be validated in
cohorts undergoing ablation with newer ablation catheters
or techniques.
The follow-up period of five derivation studies has some
differences (see Table 2). Patients in these studies were
followed up at least 12 months. Arrhythmia symptom with
12-lead ECG evidence and continuous Holter ECG monitor
were used to detect AF recurrence. Patients accepted 7-day
Holter for every 3 months in studies on the ALARMEc and
APPLE scores, and then once a year in the study on the
ALARMEc score. Of the validation cohort of the CAAP-
AF score, patients accepted 24–48 h Holter every
3–12 months but switched to 7–14-days Holter after 2006.
Patients of the BASE-AF2 cohort were only accepted with
24 h Holter every 3 months. In the MB-LATER cohort,
patients underwent 12-lead ECG and 24 h Holter at dis-
charge, 1, 3, and 6 months after procedure, and then every
6 months thereafter. If patients complained with symptoms
suggestive of arrhythmia recurrence, more extensive
arrhythmia monitoring would be performed. Asymptomatic
AF sometimes occurred much more frequently than
symptomatic AF [53]. None of these studies use implanted
recorder to detect the arrhythmia recurrence which makes
their estimation of AF recurrent rate suboptimal. For
expense or non-invasive reason, wearable instrument
which was usually used to avoid unnecessary ICD
implantation might take as the substitution [54]. Testing
studies on these scores with much precise recurrent AF rate
may help to improve overcome this limitation. Some evi-
dence has shown that the two ablation techniques with
cryoablation and radiofrequency had similar efficacy [49]
in patients with paroxysmal AF, but evidence in persistent
AF is scarce.
The CHADS2, CHA2DS2–VASc, and R2CHADS2
scores, which are not rhythm-related risk scores, were
tested in different cohorts with conflicting results. The
HATCH score had no significant value on predicting the
recurrence after CA [21]. Three clinical scores determined
before the CA procedure could be used to predict AF
recurrence post CA. In the studies describing the ALAR-
MEc and CAAP-AF scores [23, 28], the scores’ predictive
value for repeated CA outcome was also evaluated. Vali-
dation tests of the ALARMEc score were contradictory and
the CAAP-AF score was not validated by any other cohort.
For now, the APPLE score has been validated in at least
three cohorts (AUC 0.634, 0.617, and 0.716, all P\ 0.05)
including the derivation cohort of MB-LATER score. Risk
factors of the APPLE score are easily acquired clinical
indices, which makes this score a good predictor of AF
recurrence post CA.
For early recurrence based on clinical factors after the
CA procedure, the BASE-AF2 and MB-LATER scores
[25, 29] could be used to predict AF recurrence post CA.
The predictive value of BASE-AF2 is perhaps more limited
given the derivation study design. The MB-LATER score
was newly derived and validated for the predictive value of
VLAFR and compared to the other six scores except for the
CAAP-AF score. The MB-LATER score was shown to
have better predictive value for VLAFR than other scores
in a small prospective cohort (n = 133) study. Although
there is only one report for now, the MB-LATER score
appeared to be a good tool to predict VLAFR, but the value
for AF recurrence after CA needs to be further validated. In
the validation studies of the APPLE and the MB-LATER
score, different points or cut-off analyses were carried out.
Overall, the predictive value of all these scores still
requires more validation studies to help decision-making
on AF recurrence ablation or postablation outcomes.
Limitations
The majority of the derivation studies used to develop these
scoring systems had observational retrospective designs
and some scores lacked external validation cohorts. In
addition, patients who undergo cryoablation usually have
less risk factors. Based on our review, all scores were
derived from different cohorts, which made components of
them rather different. Our purpose was to report every
clinical score that had been derived and try to compare
their reported clinical predictive value(s) in relation to CA
method(s). While we fully recognize that cryoablation is
one type of ablation method/technology, but a recent report
from the Fire and Ice trial [ref] showed it had similar
outcomes to PAF patients undergoing RF ablation. Per-
sistent AF may need additional ablation approaches, such
as linear lesion (LL), but meta-analysis does not suggest
that LL following pulmonary vein isolation (PVI) provides
additional benefit for sinus rhythm maintenance. Given the
possible heterogeneity of reported cohorts and also that our
focus was not on ablation technique, our review does not
focus on outcomes in relation to comparison of ablation
methods. Finally, the predictive value of the scores on AF
progression and recurrence requires to be confirmed in
future studies. Large cohorts should be used to test all these
scores to confirm their clinical applicability. Case studies
from different centres often not large, multicentre clinical
trial data or different centre combining the data might be of
help like the derivation of the TIMI-AF score [55] and the
AF-CVS score [56]. Until large prospective cohorts exist,
we should regard application of these scores as hypothesis
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generating, but using these scores may provide some
insights on who may (or may not) do well following
ablation.
Conclusion
Several predictive scores for rhythm outcome of AF
recurrence postCA have been developed and tested, but
evidence of their predictive value still requires further
evaluation. Many risk factor components of these scores
have been reported as independent predictors of CA out-
come, whether directly or indirectly contributing to AF
substrate formation. For now, the risk scores for recur-
rences following CA have limited validation.
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